Gene · 4144
Papers1,624
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,624
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hallmarks of nuclear metabolism: implications for genome integrity, nuclear signaling, and therapeutic targeting. | NPJ Metab Health Dis | 2026 | 41629581 | PubTator, text mining | PubMed |
| Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase In Vitro. | Anticancer Res | 2026 | 41617456 | PubTator, text mining | PubMed |
| Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications. | Signal Transduct Target Ther | 2026 | 41582215 | PubTator, text mining | PubMed |
| Methionine adenosyl-transferase 2A promotes placental angiogenesis by regulating VEGF-A translation via the mTORC1 signalling pathway. | J Physiol | 2026 | 41579147 | PubTator, text mining | PubMed |
| Integrative analysis of nanopore direct RNA sequencing data reveals a global impact of pseudouridylation on m6A and m5C modifications. | NPJ Precis Oncol | 2026 | 41571893 | PubTator, text mining | PubMed |
| Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies. | Gynecol Oncol Rep | 2026 | 41567617 | PubTator, text mining | PubMed |
| Methionine restriction for cancer therapy: From preclinical studies to clinical trials. | Cancer Pathog Ther | 2026 | 41550357 | PubTator, text mining | PubMed |
| The AHCY-adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesis. | Cell Res | 2026 | 41549122 | PubTator, text mining | PubMed |
| METTL16 Inhibits Lens Epithelial Cells Function in Diabetic Cataract via m6A-Modified DKK1-Mediated Wnt/β-Catenin Signaling. | Invest Ophthalmol Vis Sci | 2026 | 41533902 | PubTator, text mining | PubMed |
| Design, Synthesis, and Preclinical Evaluation of a PET Tracer Targeting Methionine Adenosyltransferase 2A. | J Med Chem | 2026 | 41530967 | PubTator, text mining | PubMed |
| MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma. | Commun Biol | 2026 | 41530371 | PubTator, text mining | PubMed |
| Integrative analysis of proteomics and metabolomics reveals amino acid metabolism disorder in adriamycin-resistant acute myeloid leukemia cells. | Sci Rep | 2026 | 41513813 | PubTator, text mining | PubMed |
| MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario. | Cancer Res | 2026 | 41512197 | PubTator, text mining | PubMed |
| Silencing of MAT2A inhibits gastric cancer cell proliferation, migration, and invasion through activation of the p53 pathway. | Clin Transl Oncol | 2026 | 41419675 | PubTator, text mining | PubMed |
| Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC. | J Thorac Oncol | 2026 | 41260457 | PubTator, text mining | PubMed |
| Glioinflammation: disease-associated microglia and astrocytes in psychiatric disorders, neurodegeneration, and senescence. | Front Cell Neurosci | 2025 | 41783158 | PubTator, text mining | PubMed |
| Redefining orthopaedic translation: Harnessing multi-omics, smart biomaterials, and regenerative immunomodulation. | J Orthop Translat | 2025 | 41542101 | PubTator, text mining | PubMed |
| Regulation of INSM1 Gene Expression and Neuroendocrine Differentiation in High-Risk Neuroblastoma. | Biology (Basel) | 2025 | 41514864 | PubTator, text mining | PubMed |
| Tumor-associated neutrophils drive liver-specific metastatic progression in breast cancer through methionine metabolism mediated by methionine adenosyltransferase II alpha. | Transl Cancer Res | 2025 | 41510096 | PubTator, text mining | PubMed |
| MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting. | Int J Mol Sci | 2025 | 41465382 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4144/papers?page=3